Studies of NSCLC patients receiving anti-PD-1/PD-L1 drugs have found that significant decreases in ctDNA levels are linked to immunotherapy clinical response and prolonged survival [102, 103]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.